BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solve ME/CFS Initiative
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20220407T100000
DTEND;TZID=UTC:20220407T110000
DTSTAMP:20220309T210703Z
CREATED:20220303T053514Z
LAST-MODIFIED:20220309T210703Z
UID:33495-1649325600-1649329200@solvecfs.org
SUMMARY:ME/CFS: NO problem?
DESCRIPTION:Nitric oxide (NO) – a gas produced by cells lining the blood vessels (endothelial cells) – helps to promote the widening of blood vessels (vasodilation) and is involved in the immune and metabolic systems. This key process allows oxygenated blood to reach tissues throughout the body. The production of NO increases in response to physical activity in healthy individuals. However\, their findings in vitro suggest that ME/CFS patients might have a reduced ability to produce NO. \nOver the next few months\, Ramsay Researcher Dr. Francisco Westermeier and his team aim to expand the existing evidence by analyzing several biochemical pathways and metabolites responsible for NO production. \nIn this webinar\, Dr. Westermeier will discuss this Solve M.E.- supported project that uses samples from the UK ME/CFS Biobank. \nRegister here.
URL:https://solvecfs.org/event/me-cfs-no-problem/
LOCATION:Online
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/03/Add-a-heading.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220316T130000
DTEND;TZID=UTC:20220316T140000
DTSTAMP:20220310T165716Z
CREATED:20220310T165208Z
LAST-MODIFIED:20220310T165716Z
UID:33573-1647435600-1647439200@solvecfs.org
SUMMARY:Implications of ME/CFS Case Definitions for Long Covid
DESCRIPTION:Our friends at the U.S. Action Working Group are hosting Dr. Leonard Jason\, Professor of Psychology DePaul University\, for a special webinar event. \nLeonard Jason’s talk will cover the content below: \nEvery disease has a case definition\, and these entities are crucial\, as they allow patients to have a diagnosis for a constellation of symptoms as well as for scientists who can research those with the illness versus those without the illness. If difficulties occur in arriving at a reliable case definition\, there are serious consequences for patients\, as they would then be unsure whether or not they have the illness\, as well as for scientists\, who might then have difficulties in estimating prevalence as well as finding biomarkers. This has occurred for the post-viral illness that is known as ME/CFS and has already begun to occur for Long COVID. The consequences have been increased stigma for patients as to when patient heterogeneity makes it difficult to identify biomarkers\, and when they are not identified\, health care workers can easily attribute the condition to solely psychiatric reasons. The relevance of ME/CFS takes on even greater importance given recent findings that a PASC-anticipating risk factor at the time of initial COVID-19 diagnosis is the Epstein-Barr virus viremia\, which has also been associated with ME/CFS. \nRegister here.
URL:https://solvecfs.org/event/implications-of-me-cfs-case-definitions-for-long-covid/
LOCATION:Online
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/03/Jason2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220308T100000
DTEND;TZID=UTC:20220308T110000
DTSTAMP:20220301T021217Z
CREATED:20220222T234740Z
LAST-MODIFIED:20220301T021217Z
UID:33308-1646733600-1646737200@solvecfs.org
SUMMARY:Chronic Illnesses in Women: ME/CFS and Migraine
DESCRIPTION:Join us for this event in which ME/CFS & migraine comorbid communities collaborate to bring together patients\, researchers\, and doctors to discuss ME/CFS\, migraine disorders\, and their impact on women’s health. This webinar\, hosted by Solve M.E. and the Association for Migraine Disorders\, will feature presentations by Dr. James Baraniuk (Director of the Chronic Pain and Fatigue Research Center\, Georgetown University Medical Center)\, Dr. Nancy Klimas (Director\, Institute for Neuro-Immune Medicine)\, and community members Georgia Linders and Melinda Lipscomb. \nPlease join us March 8\, International Women’s Day\, at 10 am PT. 
URL:https://solvecfs.org/event/chronic-illnesses-in-women-me-cfs-and-migraine/
LOCATION:Online
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/02/TW-Migraine-ME_CFS-Webinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220215T150000
DTEND;TZID=UTC:20220215T160000
DTSTAMP:20220107T001148Z
CREATED:20211209T174806Z
LAST-MODIFIED:20220107T001148Z
UID:31571-1644937200-1644940800@solvecfs.org
SUMMARY:Using Data Analysis to Study ME/CFS and Long Covid: Session 2
DESCRIPTION:We expanded our Ramsay Grant Program in 2021 by launching the new Stupski Awards\, which support research using data from the Registry. These webinars feature the 2021 Stupski Award recipients\, Efthymios Kalafatis and Jennifer Stone\, PhD\, who will discuss their research and answer your questions. \nJennifer Stone\, PhD\nAustralian National University \nDr. Stone will discuss her Stupski-supported project\, which uses advanced analytic methods to compare important demographic and clinical characteristics in people with ME/CFS to Long Covid controls and healthy controls. \nDr. Stone recently received her PhD in clinical epidemiology from Australian National University. She has co-authored several journal articles using data and modeling to uncover causes of disease. Jennifer earned her BA and MPH from the University of Queensland. \nSession II\nFebruary 15\, 2022\n3 pm PT\nPlease click here to register.
URL:https://solvecfs.org/event/using-data-analysis-to-study-me-cfs-and-long-covid-session-2/
LOCATION:Online
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2021/12/revised.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220210T130000
DTEND;TZID=UTC:20220210T140000
DTSTAMP:20220112T171934Z
CREATED:20220112T171934Z
LAST-MODIFIED:20220112T171934Z
UID:32642-1644498000-1644501600@solvecfs.org
SUMMARY:Solve Spotlight: Writer Nadine Sander-Green in Conversation with Joe Komsky
DESCRIPTION:Before developing ME/CFS\, Canadian writer Nadine Sander-Green was an avid adventurer\, canoeing down rapids\, mountain-biking along rugged trails\, and skiing through waist-deep powder. Post-diagnosis\, she’s written in detail about her journey towards the acceptance of her new body and living within drastically smaller limits. \nIn this webinar\, Nadine talks to Solve M.E. Development Director Joe Komsky about her ME/CFS experience\, the impact of the disease on multiple family members\, and why the accurate and nuanced representation of people with ME/CFS in storytelling is so crucial to progress.
URL:https://solvecfs.org/event/solve-spotlight-writer-nadine-sander-green-in-conversation-with-joe-komsky/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/01/SanderGreenWebinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220210T120000
DTEND;TZID=UTC:20220210T130000
DTSTAMP:20220127T175259Z
CREATED:20220127T175259Z
LAST-MODIFIED:20220127T175259Z
UID:32994-1644494400-1644498000@solvecfs.org
SUMMARY:Long COVID & Fatiguing Illness Recovery Program ECHO
DESCRIPTION:(continuing on the 2nd Thursday of each month) \nNeurocognitive Manifestations of PASC \nMichelle Haddad\, PhD\nAssistant Professor\, Department of Rehabilitation Medicine Emory University School of Medicine \n  \n\n\n\nFamily Health Centers of San Diego\, the ECHO Institute\, University of Washington\, and University of Colorado have collaborated to provide a CDC-funded monthly webinar-style ECHO learning session to rapidly disseminate Post-acute Sequelae of SARS-COV-2 infection (PASC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) findings and emerging best practices. This large-scale national monthly ECHO webinar series will offer didactic presentations by subject matter experts\, examples of emerging best practices and models of care\, and a facilitated Q&A. This program is open to all healthcare professionals and all Long COVID and ME/CFS patient-lived experience experts interested in learning more about the treatment of Long COVID and ME/CFS.
URL:https://solvecfs.org/event/long-covid-fatiguing-illness-recovery-program-echo/
LOCATION:Online
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/01/Untitled-design-7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220127T110000
DTEND;TZID=UTC:20220127T120000
DTSTAMP:20220125T182836Z
CREATED:20211227T221549Z
LAST-MODIFIED:20220125T182836Z
UID:31856-1643281200-1643284800@solvecfs.org
SUMMARY:Ampligen: A General Overview and the Plan for ME/CFS & Long Covid
DESCRIPTION:For the second installment in our clinical diagnostics and treatments webinar series\, Solve M.E. welcomes two leaders from bio-pharma company AIM ImmunoTech to discuss their plans for clinical studies of their investigational drug Ampligen\, in ME/CFS and Long Covid. In addition\, Drs. Lapp and Gottschalk will share insights from real-world use of Ampligen to treat patients with ME/CFS and Long Covid. \nAmpligen (Rintatolimod)\, is a drug that modulates the immune system and has anti-viral activity. It has been studied in clinical trials since the late 1980s\, and although it has been endorsed by countries outside the USA specifically for treating people with ME/CFS\, it does not have FDA approval. AIM has recently updated its plans for developing the drug in ME/CFS and Long Covid. \nThe application of Ampligen for both diseases is yet another example of how ME/CFS research can benefit people with ME/CFS and Long Covid\, and why the study of both is crucial to each community. \nJoin Solve President and CEO Oved Amitay in conversation with Thomas K. Equels\, M.S.\, J.D. (Chief Executive Officer\, AIM)\, and David R. Strayer\, M.D (Chief Scientific & Medical Officer\, AIM) to learn more about their plans for Ampligen and how the community may get involved. Dr. Charles Lapp (Medical Director\, Hunter-Hopkins Center) will discuss his use of Ampligen as a treatment for both ME/CFS and Long Covid\, and Dr. Gunnar Gottschalk (Executive Director/PI\, Simmaron Research Inc)\, will share data on the use of Ampligen in people with ME/CFS. \nRegister for the webinar here. \nDo you have a question for our panelists? Submit it to us at SolveCFS@solvecfs.org \nTo view the first webinar in our clinical diagnostics and treatments webinar series\, “Immune-Based Prediction of Long Covid and Implications for ME/CFS “ featuring Dr. Bruce Patterson\, click here.
URL:https://solvecfs.org/event/ampligen-a-general-overview-and-the-plan-for-me-cfs-long-covid/
LOCATION:Online
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2021/12/Ampligen-FB-IG.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220121T100000
DTEND;TZID=America/Los_Angeles:20220121T110000
DTSTAMP:20220107T001640Z
CREATED:20211130T142746Z
LAST-MODIFIED:20220107T001640Z
UID:22804-1642759200-1642762800@solvecfs.org
SUMMARY:Using Data Analysis to Study ME/CFS and Long Covid: Session 1
DESCRIPTION:We expanded our Ramsay Grant Program in 2021 by launching the new Stupski Awards\, which support research using data from the Registry. These webinars feature the 2021 Stupski Award recipients\, Efthymios Kalafatis and Jennifer Stone\, PhD\, who will discuss their research and answer your questions. \nEfthymios [Themos] Kalafatis\nData Scientist/Machine Learning Engineer \nKalafatis will discuss tracking his ME/CFS symptoms and analyzing the data and how that led to his Stupski-funded project\, which applies powerful machine learning and text analysis methods to better understand symptoms\, identify potential associations with treatments and life events and examine models of temporal patterns. \nKalafatis has over 20 years of data and text mining experience and holds a patent on a methodology that uses machine learning\, network analysis and natural language processing for medical research. He has applied artificial intelligence techniques to research ME/CFS and natural language processing methods to analyze patient records. Themos has a BA from the University of Portsmouth and a MSc from the University of East Anglia. \nSession I\nNEW DATE: January 21\, 2022\n10-11 am PT\nPlease click here to register.
URL:https://solvecfs.org/event/using-data-analysis-to-study-me-cfs-and-long-covid-session-1/
LOCATION:Online
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2021/12/revised.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20211206T110000
DTEND;TZID=America/Los_Angeles:20211206T120000
DTSTAMP:20220107T001420Z
CREATED:20211130T151838Z
LAST-MODIFIED:20220107T001420Z
UID:22819-1638788400-1638792000@solvecfs.org
SUMMARY:Immune-Based Prediction of Long Covid and Implications for ME/CFS
DESCRIPTION:Dr. Bruce Patterson is the CEO of IncellDx\, where he is developing a new paradigm for predicting\, identifying\, and treating people with Long Covid. \nDr. Patterson’s published scientific work suggests that Long Covid patients can be diagnosed reliably by analyzing patterns in cytokines- different types of proteins produced by a person’s immune system. Identifying a Long Covid immune system “fingerprint” may lead to a better understanding of the disease and to new treatment approaches that address the underlying causes. \nIn this webinar\, Dr. Patterson will describe his recent findings in COVID-19 and different pathogens that impair the immune system’s ability to function effectively\, and their implications for other diseases\, including ME/CFS. \nDr. Patterson made significant contributions to the diagnosis of HIV/AIDS and previously served as medical director of diagnostic virology at Stanford University School of Medicine.
URL:https://solvecfs.org/event/immune-based-prediction-of-long-covid-and-implications-for-me-cfs/
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=:
END:VEVENT
END:VCALENDAR